Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
NCT03493646Phase 2Completed
- Sponsor
- The Kirby Institute
- Start
- May 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of CC-486 in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), sponsored by The Kirby Institute. Started May 2018; status: completed.
02
Drugs
CC-486
03
Conditions
myelodysplastic syndromes (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03493646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493646.